Dear Ms. Glauberzon:

Please refer to your Supplemental New Drug Application (sNDA) dated November 5, 2010, received November 5, 2010 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Taxol® (paclitaxel).

We acknowledge receipt of your amendments dated December 6, 2010, January 11, 2011 and January 20, 2011.

This “Changes Being Effected” supplemental new drug application proposes to update the ADVERSE EVENT EXPERIENCES BY BODY SYSTEM, Other Clinical Events subsection to include postmarketing experience information regarding skin abnormalities.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.


The SPL will be accessible from publicly available labeling repositories.
Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Dr. Mona Patel, Regulatory Project Manager, at (301) 796-4236.

Sincerely,

/Jeffery Summers/
Jeffery Summers, M.D.
Deputy Director for Safety
Division of Biologic Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

ENCLOSURE: Package Insert
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JEFFERY L SUMMERS
05/02/2011